Introduction
The use of highly active antiretroviral therapy (HAART) has been associated with declines in mortality, opportunistic infections and hospitalizations (Mocroft et al., 1998; Mocroft et al., 2004; Palella et al., 1998) . The introduction of HAART has resulted in significantly higher costs for therapeutics, while reductions have been observed in healthcare resource use due to the prevention of opportunistic infections (Gebo, Chaisson, Folkemer, Bartlett, & Moore, 1999) . Since the mid-1990s, this has resulted in a shift from inpatient towards outpatient care, which has been reported by several authors (Garattini, Tediosi, Di Cintio, Yin, & Parazzini, 2001; Tramarin, Postma, Gerzeli, Campostrini, & Starace, 2004) . However, a recent review by Levy et al. (2006) on the direct costs of HIV/AIDS care revealed that there are few recent studies that provide adequate information on the costs of HIV/AIDS care. Even fewer studies evaluate the indirect costs of HIV/AIDS care, although indirect costs should formally be included when evaluating healthcare interventions from the societal perspective (Drummond, Sculpher, Torrance, O'Brien, & Stoddart, 2005) .
Although HIV/AIDS care is a societal obligation to which many governments are committed regardless of economic considerations, nevertheless more accurate information on the societal costs of HIV/AIDS care will allow decision makers to better understand its economic impact. Given the fact that HIV prevalence rates are increasing due to falling death rates, the impact of HIV on national health budgets can be expected to increase (UNAIDS, 2007; Yazdanpanah et al., 2002) . The cost estimates of this paper can provide a basis for decision makers to assess the economic impact on different stages of disease and make better informed choices regarding the resource allocation of HIV/AIDS care.
Italy has the third highest prevalence of AIDS cases (after France and Spain) in Western Europe. In Italy about half (58%) of AIDS cases are injection drug users. Italy was estimated to have around 56,076 prevalent cases of AIDS at the end of 2005 (Suligoi et al., 2006) . Prior studies on the costs of AIDS in Italy have led to the establishment of a growing research network involving over 30 AIDS clinics in North-east Italy. In 1994, and again in 1998, an Italian team conducted two separate surveys of the quality of life (QoL) and the medical costs of these patients (Tramarin et al., 2004) . Remarkable changes occurred over this four-year period Á increasing drug costs, decreasing hospital costs and improved QoL. The availability of historical data as well as an existing research network renders Italy suitable for a detailed assessment of costs for HIV/AIDS.
In this study, we provide an assessment of the direct medical costs and indirect costs of HIV/AIDS care in Northern Italy.
Methods

Study design
The study was designed as a prospective longitudinal cohort study with a timeframe of 12 months. A sample of patients was gathered from the infectious disease clinics of two major hospitals in Northern Italy: ''Ospedale Civile di Padova'' in Padua and ''Ospedale L. Sacco'' in Milan. Eligibility criteria included age over 18, mental competence, and agreement to be compliant with medical care and follow up. Patients were surveyed at baseline and were followed-up at 6 and 12 months. To assess the relationship between costs and stage of disease, patients were categorized into three groups at baseline depending on pre-exposure to HAART and severity of symptoms The category ''No HAART'' included HIV positive, asymptomatic patients who had CD4 counts sufficiently high so that they had never been on HAART. Patients were categorized in the second category ''Stable HAART'', if they had been on HAART with mild HIV infection. Mild infection was defined as having a CD4 count over 200 cells/?l and no prior opportunistic infections. The third category ''HAART failure'' included patients whose primary HAART regimen had to be altered because of severe side effects or immunological failure. These patients had to meet the following criteria:
(1) the patients had been on a primary HAART regimen for at least 12 weeks and had either (2a) their HAART regimen switched, stopped, or reconsidered in last 12 weeks because of immunological failure as documented by viral load and CD4 count or (2b) had major toxicity (lipodystrophy or metabolic changes) from their HAART regimen. To enable a prospective estimate of the cost of caring for a patient for subsequent 12 months based on initial clinical stage, patients maintained their original classification throughout the study. Thus patients in ''No HAART'' and ''Stable HAART'' categories were not reclassified if their clinical stage advanced at later rounds of data collection. Subjects were then offered enrolment on a ''first come first serve'' basis until the enrolment quota (20 for each category at each clinic) for that category was reached. Informed consent from patients was gathered and the hospital ethics committees in both Milan and Padua determined that this study was exempt from human subject restrictions, as no interventions were being imposed and patients' identities were not being entered into the database. The Johns Hopkins Bloomberg School's Committee on Human Research approved the analysis of the secondary dataset and labelled this study as 'protecting human subjects'.
Cost and quality of life data
We used a bottom-up analysis (Drummond et al., 2005) to estimate annual direct costs by counting resource use at the patient level and multiplying these with the unit prices. Resource use data was registered monthly in a cost tracking database by clinical staff. This included data on ARV drug use, (day) hospital admissions, diagnostic procedures, laboratory tests, clinic visits and consultations. Costs of drugs were calculated at 50% of the market price, representing the official drug price to the hospitals in Italy. All unit costs of medical resources are based on the National Tariff System (Minestero della Salute, 2004) . Indirect costs were calculated using data collected with the ''Short Form Health and Labour Questionnaire'' (SF-HLQ) (van Roijen et al., 1996) that was completed at baseline an at each visit. In addition, we examined rates of labour force participation and earnings as reported by the patient. Production losses were calculated assuming an average number of annual working hours in Northern Italy of 1729 with a working day of 8 hours (Eurostat, 2004) . For indirect costs we included production losses due to absence from work, reduced productivity at work and reduced unpaid labour participation. Production losses due to absence from work were calculated using the human capital approach (Drummond et al., 2005) . Production losses due to reduced productivity at work were calculated using the method proposed by Osterhaus, Gutterman and Plachetka (1992) . Production losses due to reduced unpaid labour participation, i.e. the costs of time spent by household members or others on unpaid work that would have been performed by the patient, were estimated and valued using the average income of a household help in Northern Italy (Eurostat, 2004) . All costs are reported in Euros using price levels of 2004.
At baseline and at each visit each the patient completed the AIDS Clinical Trials Group 601-2 Form which consisted of a Medical Outcomes Study HIV questionnaire as well as a visual analogue rating scale rating their current health state from 0 to 100. This visual analogue rating was interpreted as the patient's current QoL. Additionally, a symptom tracking patient questionnaire was filled out monthly by the patient, registering the number of days per month that the patient was free of HIV symptoms or adverse drug effects.
Statistical analysis
We used a two-part method to model the fact that patient cost data may contain zero costs in high frequencies in subcategories. Subsequently, parametric regression methods were used to the nonzero cost data, which tend to be not normally distributed and skewed in nature. In particular, to assess the problem of zero costs, we fitted a Generalized Linear Model, in order to determine the odds of a patient having non-zero costs, as described by Zhou, Qin and Maciejewski (2006) . Subsequently, in order to estimate the expected value and the standard deviation of the non-zero and skewed cost data, we made the assumption that it follows a lognormal, generalized gamma or generalized F distribution. As described by Peng, Dear and Denham (1998) the generalized F has the advantage of including a wide variety of distributions as special cases (such as Weibull, lognormal, log-logistic). Estimation of the distribution parameters was done with the method of maximum likelihood. The distribution that fitted best was selected using the Akaike criterion (Peng et al., 1998) . The expected value and standard deviation of the non-zero costs was calculated through the moments of the distribution used (Kalbfleisch & Prentice, 2002; Basu, Manning, & Mullahy, 2004) . Subsequently, these values in combination with the probability of a patient having zero costs were used to estimate the total expected value and standard deviation (Basu et al., 2004; Zhou et al., 2006) . This method produces consistent estimates of mean costs. To compare the costs by clinical category a parametric regression model was used. For the analysis of QoL, the expected value and standard deviation of the patients' QoL was calculated through the moments of a beta distribution that was fitted to the data. Subsequently, beta regression analyses were performed to investigate the determinants of the patients' QoL (Ferrari & Cribari-Neto, 2004) . The likelihood ratio test was used to select the best fitting model. The statistical analysis was carried out using Stata 9.2 (StataCorp, 2005) and R 2.5.0 (R Development Core Team, 2007) .
Results
Enrolment began in January 2004 and ended May 2004. Enrolment was offered to 165 patients. A total of 121 patients agreed to enrol. The follow-up phase began 12 weeks after enrolment and continued for a subsequent period of 56 weeks. After enrolment, 2 patients were lost to follow up, leaving a sample of 119 that were surveyed at baseline. After the survey at 6 months, 6 more patients were lost to follow up, leaving a final sample for analysis of 113 patients that were surveyed at 12 months and that completed follow up. The characteristics of the sample population are shown in Table 1 .
Direct and indirect costs
The annual cost estimates per patient for the main cost categories are shown in Table 2 , together with the expected annual earnings. Parametric regression analysis showed that compared to ''No HAART'', ''Stable HAART'' and ''HAART failure'' had significantly higher ARV drug costs, direct costs and total costs. The significant differences in total costs were primarily due to the low cost of ARV drugs in the ''No HAART'' group (Some ARV drug costs also occured in ''No HAART'' because the categories were defined at baseline and 10 out of the 37 patients in ''No HAART'' were started on HAART during the follow-up phase). Comparing ''HAART failure'' to ''Stable HAART'', significantly higher direct costs were found. ARV drugs contribute to direct costs but are shown as a separate category because of their large share in total costs. Included in ''Direct Costs Á excluding ARVs'' are (day) hospital admissions, clinic visits, consultations, laboratory tests (haemochrome; CD4; viral load; panel 8; panel 20; single dose; blood-, urine-, CSF-, cryptococcal culture; toxo serology) and procedures/treatments (chest X-ray; tomography; CT scan; echogram; ECG; gastroscopy; blood transfusion; immunoglobulin-amphotericin-, erythropoietin-, daunorubicine-, chemotherapy-infusion).
Of the distributions tested, the lognormal and generalized F distributions were found to describe the AIDS Care 451 different cost categories best. Since the goodness of fit of these distributions on the data varied per category, the expected value of the total costs is not equal to the sum of the expected values of the individual categories. Figure 1 shows the proportion of aggregated annual total costs of the cohort for the main cost categories, by clinical category. The contribution to the total aggregated costs of the cohort of the subcategories of direct and indirect costs are shown in Table 3 .
Quality of life
The expected value (and standard deviation) of the patients' QoL over the study period for ''No HAART'', ''Stable HAART'' and ''HAART failure'' was estimated at 0.80 (0.16), 0.78 (0.17) and 0.64 (0.20), respectively. For the beta regression analysis, we considered as baseline a patient in ''No HAART'', with a QoL equal to the expected value, without any household members, no paid work and experiencing symptoms all days of the month. The regression analysis showed a significant positive relation between the patients' QoL and the determinants ''having paid work'' (0.25 p=0.0114) and ''monthly days without symptoms'' (0.029 p=0.0158). The patients' QoL was significantly lower in ''HAART failure'' compared to ''No HAART'' ( (0.61 pB0.001), ,but not significantly different between ''Stable HAART '' and ''No HAART (0.054 p=0.683) . Hence, compared to a baseline patient, the difference in the QoL of a patient in ''HAART failure'', experiencing 15 days per month without symptoms (all other variables remaining equal to baseline) would be (16.1% ((exp(1* (0.61'15*0.029) (1) *100%).
Discussion and conclusion
This study assesses the impact of HIV/AIDS on costs and QoL in a cohort of Italian HIV/AIDS patients. Patients were categorized by progression of disease. The total costs for patients in ''No HAART'' (expected value: t1818) were over six times lower than for patients in ''HAART failure'' (expected value: t12,332) and over five times lower than for patients in ''stable HAART'' (expected value: t9820).
Comparing ''Stable HAART'' to ''HAART failure'', we only found significantly higher direct costs. These higher direct costs are related to a higher occurrence of diagnostic procedures, consultations and laboratory tests in ''HAART failure''. The ARV drug costs for patients in ''HAART failure'' were found to be higher than for patients in ''stable HAART'', although this difference was not significant. A difference was expected, since the composition of therapeutic regimens of this latter category included more expensive drugs (e.g. enfuvirtide) and was associated with a more frequent use of protease inhibitors which have a higher cost than NNRTI (29% in ''stable HAART'', versus 41% in ''HAART failure''). Looking at the entire cohort, the costs of ARV medication made up the majority of costs, with ARV drug costs contributing 36%, 76% and 72% of aggregated total costs in ''No HAART'', ''Stable HAART'' and ''HAART failure'' respectively.
The shift in costing patterns from inpatient to outpatient care in Italy as published by a number of authors (Garattini et al., 2001; Torti et al., 2003; Tramarin et al., 2004) was confirmed by our study results, and furthermore, our results indicate that the shift has continued to the point where the contribution of inpatient care costs to the total costs for Figure 1 . Total aggregated costs of the cohort by clinical category, subdivided by antiretroviral drug costs, direct cost excluding antiretroviral drugs and indirect costs. Also shown are the percentages of the total costs in each the clinical category. Table 3 . Total aggregated direct costs of the cohort by clinical category, subdivided by antiretroviral drugs, laboratory tests, procedures, consultations and inpatient care. Also shown are total aggregated indirect costs of the cohort by clinical category, subdivided by production losses due to absence from work, production losses due to reduced productivity at work and costs due to reduced unpaid labour participation.
Clinical category
No HAART Stable HAART HAART failure HIV/AIDS treatment has become almost negligible. During our study only two inpatient stays were observed in our cohort. The indirect costs consist mainly of production losses due to absence from work and reduced productivity at work. The indirect costs are comparable in magnitude to the direct costs excluding ARVs. These high indirect costs can be explained by the relatively young population and corresponding higher labour participation of the cohort. In Table 5 , when comparing the indirect costs of ''Stable HAART'' to ''HAART failure'', we see lower production losses due to absence from work combined with higher production losses due to decreased productivity at work. This result suggests that a stable HAART regimen allows a patient to come to work although at a lower productivity. The estimates of the annual earnings show that significant amounts are being earned by this patient population, potentially exceeding the direct treatment cost for these groups of HIV/AIDS patients.
The impact of HIV/AIDS on QoL in all patient groups was clearly visible, with patients in ''No HAART'' (expected value: 0.80) having the highest QoL score, followed by patients in ''stable HAART'' (expected value: 0.78) and ''HAART failure'' (expected value: 0.64). The multivariate regression analysis showed a high association between patients' QoL and having paid work, but provided no evidence on causality.
In this study, we used a prospective study design. The primary advantage of the prospective and longitudinal study design is that it avoids bias due to selective recall. The prospective design allowed patients to maintain symptom diaries and staff at the clinical practice to register all costs in real time. The inclusion of both a 6-month and a 12-month followup offered participants an opportunity to gain more experience with the study instruments. The Italian healthcare setting for HIV offers excellent data gathering opportunities, since in Italy, HIV/AIDS patients are exclusively followed up by infectious diseases specialists. All outpatient prescription drugs are dispensed in the outpatient clinic (not pharmacies) so that information on drug utilization is available from the medical record, and the same clinicians are responsible for both outpatient and inpatient care.
Levy et al. observed in a recent review on the direct costs of HIV/AIDS care a lack of comparability of studies because of different costing methods used and differences in the classification of patients.
In this study, we used similar costing methodologies as Tramarin et al. (2004) , but the statistical analysis was different, making results also difficult to compare. According to this previous study, direct medical costs due to HIV/AIDS care amounted to t17,250 per person year in 1994, and t11,465 per person year in 1998. Our cost estimates are lower. This is due to the different methodology used to estimate the expected value, but it could also partially reflect the effects of lowered ARV drug prices and a continued shift in resource use from inpatient care to outpatient care. However, given the size of the cohort and number of study centres used in this study, the costing result may not be representative for the HIV/AIDS population in other regions of Italy.
An important finding is that despite being in treatment, many patients were still gainfully employed and generated substantial expected annual earnings ranging from t14,994 for ''No HAART'' to t9820 for ''Stable HAART''. These annual earnings exceeded the expected direct costs of their medical treatment and our analysis indicates that in this setting HIV/AIDS care enables a patient population to contribute an economic output that exceeds the expenditure on their treatment.
